CD274 and non-small cell lung carcinoma: investigated the impact of the synergistic combination of anti-PD-L1 therapy and anti-platelet agents amongst NSCLC patients, concluding that this synergetic combination did not significantly improve PFS or OS in the multivariate analysis (221).